GFM
GF Fund Management Portfolio holdings
AUM
$4.97B
This Quarter Return
+7.58%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$4.62B
AUM Growth
–
Cap. Flow
+$4.62B
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
48.03%
Holding
637
New
637
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
NVIDIA
NVDA
|
$390M |
| 2 |
Apple
AAPL
|
$374M |
| 3 |
Microsoft
MSFT
|
$322M |
| 4 |
Amazon
AMZN
|
$234M |
| 5 |
Meta Platforms (Facebook)
META
|
$194M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Technology | 45.53% |
| 2 | Consumer Discretionary | 17.29% |
| 3 | Communication Services | 14.35% |
| 4 | Healthcare | 6.6% |
| 5 | Consumer Staples | 4.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
376
Twist Bioscience
TWST
$1.55B
| $57.9K | ﹤0.01% |
+1,246
| New | +$57.9K |
|
377
Vericel Corp
VCEL
$1.72B
| $56.9K | ﹤0.01% |
+1,036
| New | +$56.9K |
|
378
Douglas Emmett
DEI
$2.83B
| $56.5K | ﹤0.01% |
+3,042
| New | +$56.5K |
|
|
SWTX
379
DELISTED
SpringWorks Therapeutics
SWTX
| $56.4K | ﹤0.01% |
+1,562
| New | +$56.4K |
|
380
Vera Therapeutics
VERA
$1.54B
| $56.2K | ﹤0.01% |
+1,330
| New | +$56.2K |
|
381
Legend Biotech
LEGN
$6.66B
| $55.8K | ﹤0.01% |
+1,715
| New | +$55.8K |
|
382
Kymera Therapeutics
KYMR
$3.11B
| $54.7K | ﹤0.01% |
+1,360
| New | +$54.7K |
|
383
Broadstone Net Lease
BNL
$3.53B
| $54.3K | ﹤0.01% |
+3,426
| New | +$54.3K |
|
384
Recursion Pharmaceuticals
RXRX
$2.01B
| $54.2K | ﹤0.01% |
+8,016
| New | +$54.2K |
|
385
Park Hotels & Resorts
PK
$2.4B
| $53.4K | ﹤0.01% |
+3,796
| New | +$53.4K |
|
386
Edgewise Therapeutics
EWTX
$1.64B
| $53.1K | ﹤0.01% |
+1,988
| New | +$53.1K |
|
387
Amneal Pharmaceuticals
AMRX
$3.02B
| $51.5K | ﹤0.01% |
+6,506
| New | +$51.5K |
|
388
Dyne Therapeutics
DYN
$2.02B
| $50.3K | ﹤0.01% |
+2,137
| New | +$50.3K |
|
389
NewAmsterdam Pharma
NAMS
$3.04B
| $49.9K | ﹤0.01% |
+1,940
| New | +$49.9K |
|
390
National Storage Affiliates Trust
NSA
$2.56B
| $49.7K | ﹤0.01% |
+1,311
| New | +$49.7K |
|
391
Arrowhead Research
ARWR
$4.02B
| $49.1K | ﹤0.01% |
+2,613
| New | +$49.1K |
|
392
Protagonist Therapeutics
PTGX
$3.77B
| $48.3K | ﹤0.01% |
+1,251
| New | +$48.3K |
|
393
Urban Edge Properties
UE
$2.67B
| $47.4K | ﹤0.01% |
+2,205
| New | +$47.4K |
|
394
Iovance Biotherapeutics
IOVA
$901M
| $47.4K | ﹤0.01% |
+6,400
| New | +$47.4K |
|
395
IDEAYA Biosciences
IDYA
$2.38B
| $46.6K | ﹤0.01% |
+1,815
| New | +$46.6K |
|
396
Acadia Realty Trust
AKR
$2.63B
| $46.2K | ﹤0.01% |
+1,914
| New | +$46.2K |
|
397
Four Corners Property Trust
FCPT
$2.73B
| $45.7K | ﹤0.01% |
+1,684
| New | +$45.7K |
|
398
Geron
GERN
$893M
| $44.9K | ﹤0.01% |
+12,693
| New | +$44.9K |
|
399
Tarsus Pharmaceuticals
TARS
$2.43B
| $44.5K | ﹤0.01% |
+803
| New | +$44.5K |
|
400
LXP Industrial Trust
LXP
$2.71B
| $43.4K | ﹤0.01% |
+5,349
| New | +$43.4K |
|